Skip to main content

Table 1 Drug Price Increase “Hot Spots”a

From: Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?

Price Change Distribution, Measured at the Drug Level

2013-2014

Overall

% > Medical CPI

% > 15%

% > 20%

Number of Unique Molecules in Sample

2,285

1,648

987

826

Molecule-Seller-Formulation Combinations in Sample

6,182

3,102

1,713

1,425

Percentage of Molecule-Seller-Formulation Combinations Meeting Threshold

-

50%

28%

13%

Number of Manufacturers in Sample

378

319

213

197

Percentage of total manufacturers producing molecules meeting threshold

-

84%

56%

52%

Quarterly Use (millions of units)

 Mean

7.83

7.03

7.49

7.94

 Standard Deviation

3.48

3.67

2.62

2.76

Quarterly Sales (millions of dollars)

 Average

3.66

3.78

3.53

2.83

 Standard Deviation

1.73

2.01

1.71

1.13

Price Change

 Mean

38%

93%

162%

191%

 Median

2%

17%

41%

52%

 95th Percentile

135%

249%

376%

424%

 Standard Deviation

1053%

1485%

1995%

2187%

Price Level, 2013 ($)

 Average

29.69

43.35

30.72

22.63

 Standard Deviation

378.44

521.16

385.12

292.56

Hot Spot Market Shareb

 Based on Total Extended Units Sold

-

45%

27%

23%

 Based on Total Inflation-Adjusted Sales

-

25%

12%

8%

  1. aAuthors’ calculations using IQVIA Health NSP data. All analyses used STATA 14.0 (College Station, Texas)
  2. bHot Spot market share was calculated in terms of total extended units (total extended units sold by hot spot products divided by total extend units sold of all products) and total inflation-adjusted sales (total inflation-adjusted sales of products by hot spot products divided by total inflation-adjusted sales of all products) by era